Detalhe da pesquisa
1.
T cell-dependent bispecific antibodies alter organ-specific endothelial cell-T cell interaction.
EMBO Rep
; 24(3): e55532, 2023 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621885
2.
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.
J Med Chem
; 66(19): 13384-13399, 2023 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774359
3.
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Nat Cancer
; 4(6): 812-828, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277530
4.
IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Clin Cancer Res
; 24(24): 6447-6458, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29950350
5.
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
Elife
; 52016 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27410477
6.
Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity.
Nanoscale Res Lett
; 9(1): 156, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24685243
7.
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
Elife
; 82019 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30614786